Chemotherapy Rewrites Ovarian Cancer Drug Sensibility Without Touching the Genome
Patient-derived ovarian cancer organoids show that brief chemotherapy exposure reshapes sensitivity to second-line drugs such as cediranib and topotecan without ...
Patient-derived ovarian cancer organoids show that brief chemotherapy exposure reshapes sensitivity to second-line drugs such as cediranib and topotecan without ...
Final Phase 3 IMpower030 results show that perioperative atezolizumab plus chemotherapy extended median event-free survival to 62.8 months versus 34.9 ...
© 2025 Scienmag - Science Magazine
© 2025 Scienmag - Science Magazine